Dosage/Direction for Use
Topical/Cutaneous Corticosteroid-responsive dermatoses Adult: As 0.05% ointment/cream: Apply thinly and rub gently onto the affected area once daily or bid, gradually discontinue once control is achieved. Max treatment duration of treatment: 4 weeks. Child: Same as adult dose. Max treatment duration: 7 days. |
Contraindications
Untreated cutaneous infections of bacterial, fungal, treponemal, tuberculous, or viral origin; acne vulgaris, pruritus without inflammation, perioral dermatitis, rosacea.
|
Special Precautions
Patient with psoriasis, stasis dermatitis. Not recommended for long-term use (particularly on the face). Children and elderly. Pregnancy and lactation. Patient Counselling Avoid application to the face, scalp, groin, genitals, axilla, or between toes without medical advice. Avoid contact with eyes. Do not use occlusive dressing. Avoid abrupt withdrawal. Monitoring Parameters Monitor for adrenal insufficiency and HPA axis suppression. Assess for signs and symptoms of visual disturbances.
|
Adverse Reactions
Significant: HPA axis suppression (e.g. Cushingoid features, hyperglycaemia, glycosuria), allergic contact dermatitis, bacterial or fungal super infection, increased risk of posterior subscapular cataracts and glaucoma.
Eye disorders: Blurred vision, visual disturbance.
Skin and subcutaneous tissue disorders: Pruritus.
|
Overdosage
Symptoms: Hypercortisolism or Cushing's syndrome (e.g. moon face, buffalo hump, hirsutism, weight gain), and HPA axis suppression. Management: Withdraw clobetasone gradually by decreasing the frequency of application or use less potent corticosteroids.
|
Drug Interactions
Increased systemic exposure with CYP3A4 inhibitors (e.g. ritonavir, itraconazole).
|
Action
Clobetasone is a moderately potent corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It induces phospholipase A2 inhibitory proteins (lipocortins) thereby depressing the formation, release, and activity of endogenous chemical mediators of inflammation (e.g. histamine, kinase, liposomal enzymes, prostaglandins). It also decreases the density of mast cells, chemotaxis, activation of eosinophils, and cytokine production, and inhibits the metabolism of arachidonic acid.
Absorption: May be systematically absorbed from intact healthy skin. Metabolism: Metabolised in the liver. Excretion: Via urine and bile. |
Storage
Topical/Cutaneous: Store between 15-30°C. Protect from light.
|
CIMS Class
|
ATC Classification
D07AB01 - clobetasone ; Belongs to the class of moderately potent (group II) corticosteroids. Used in the treatment of dermatological diseases.
S01BA09 - clobetasone ; Belongs to the class of corticosteroids. Used in the treatment of inflammation of the eye. |